The poor efficacy of the anti-myostatin strategy is discussed by Mariotet et al. Myostatin expression is highly reduced in atrophying DMD patients at both mRNA and serum protein levels. The gene discussed is MSTN; the disease is Duchenne muscular dystrophy.